Surgery Partners (SGRY) Depreciation & Amortization (CF) (2014 - 2026)

Surgery Partners has disclosed Depreciation & Amortization (CF) across 13 years of filings, most recently posting $39.3 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) fell 2.48% year-over-year to $39.3 million; the TTM figure through Jun 2026 stood at $177.2 million (up 10.27% YoY), while the FY2025 annual figure was $176.0 million, up 15.33% from the prior year.
• Depreciation & Amortization (CF) came in at $39.3 million for Q2 2026 at Surgery Partners, up from $38.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $59.9 million in Q4 2025 to a low of $24.4 million in Q2 2023.
• Average Depreciation & Amortization (CF) over 5 years is $35.5 million, with a median of $33.8 million recorded in 2023.
• The largest YoY upside for Depreciation & Amortization (CF) was 76.7% in 2025 against a maximum downside of 21.31% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $29.6 million in 2022, then rose by 5.07% to $31.1 million in 2023, then increased by 9.0% to $33.9 million in 2024, then soared by 76.7% to $59.9 million in 2025, then plunged by 34.39% to $39.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $39.3 million in Q2 2026, $38.5 million in Q1 2026, and $59.9 million in Q4 2025.